Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Accumulated Expenses: 2018-2025

Historic Other Accumulated Expenses for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $204,000.

  • Bicycle Therapeutics' Other Accumulated Expenses fell 48.87% to $204,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $204,000, marking a year-over-year decrease of 48.87%. This contributed to the annual value of $297,000 for FY2024, which is 15.56% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Other Accumulated Expenses stood at $204,000, which was down 13.56% from $236,000 recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Other Accumulated Expenses peaked at $1.5 million during Q4 2022, and registered a low of $64,000 during Q2 2021.
  • For the 3-year period, Bicycle Therapeutics' Other Accumulated Expenses averaged around $406,091, with its median value being $303,000 (2023).
  • Per our database at Business Quant, Bicycle Therapeutics' Other Accumulated Expenses skyrocketed by 1,396.88% in 2022 and then crashed by 82.54% in 2023.
  • Bicycle Therapeutics' Other Accumulated Expenses (Quarterly) stood at $570,000 in 2021, then skyrocketed by 158.25% to $1.5 million in 2022, then crashed by 82.54% to $257,000 in 2023, then rose by 15.56% to $297,000 in 2024, then plummeted by 48.87% to $204,000 in 2025.
  • Its Other Accumulated Expenses was $204,000 in Q3 2025, compared to $236,000 in Q2 2025 and $309,000 in Q1 2025.